Company news

Axsome Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

August 9, 2020

Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program

August 9, 2020

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy

August 4, 2020

Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020

July 29, 2020

Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder

July 12, 2020

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitation

June 25, 2020

Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting

May 28, 2020

Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually

May 25, 2020

Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update

May 7, 2020

Axsome Therapeutics to Report First Quarter 2020 Financial Results on May 8, 2020

April 29, 2020

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation

April 26, 2020

Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine

April 5, 2020

Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications

March 29, 2020

Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation

March 19, 2020

Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

March 11, 2020

Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer

March 4, 2020

Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine

February 19, 2020

Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression

January 21, 2020

Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

January 12, 2020

Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response

December 29, 2019

Axsome Therapeutics Announces Closing of $200 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 22, 2019

Axsome Therapeutics Announces Pricing of Public Offering of $174 Million of Shares of Common Stock

December 18, 2019

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder

December 15, 2019

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy

December 2, 2019

Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

November 6, 2019

Axsome Therapeutics Announces Results of MINDSET Physician Survey Affirming Unmet Need and Favorable Profile of AXS-07 in the Acute Treatment of Migraine

October 27, 2019

Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy

October 20, 2019

Axsome Therapeutics Announces Completion of Patient Enrollment in the GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder

October 15, 2019

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation

April 14, 2019

← Newer news releases

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 48 decks. Every deck is listed under its year.